{"id":51068,"date":"2022-11-21T12:03:21","date_gmt":"2022-11-21T11:03:21","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/global-parkinsons-disease-treatment-market-report-2022-market-to-reach-6-7-billion-by-2027-levodopa-carbidopa-segment-is-projected-to-record-a-6-6-cagr-and-reach-2-4-billion-researchandmark\/"},"modified":"2022-11-21T12:03:21","modified_gmt":"2022-11-21T11:03:21","slug":"global-parkinsons-disease-treatment-market-report-2022-market-to-reach-6-7-billion-by-2027-levodopa-carbidopa-segment-is-projected-to-record-a-6-6-cagr-and-reach-2-4-billion-researchandmark","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/global-parkinsons-disease-treatment-market-report-2022-market-to-reach-6-7-billion-by-2027-levodopa-carbidopa-segment-is-projected-to-record-a-6-6-cagr-and-reach-2-4-billion-researchandmark\/","title":{"rendered":"Global Parkinson’s Disease Treatment: Market Report 2022: Market to Reach $6.7 Billion by 2027 – Levodopa \/ Carbidopa Segment is Projected to Record a 6.6% CAGR and Reach $2.4 Billion – ResearchAndMarkets.com"},"content":{"rendered":"
\n

DUBLIN–(BUSINESS WIRE)–The “Parkinson’s Disease Treatment: Global Strategic Business Report”<\/a> report has been added to ResearchAndMarkets.com’s<\/strong> offering.\n<\/p>\n

<\/a><\/p>\n

\nGlobal Parkinson’s Disease Treatment Market to Reach $6.7 Billion by 2027<\/strong>\n<\/p>\n

\nIn the changed post COVID-19 business landscape, the global market for Parkinson’s Disease Treatment estimated at US$4.6 Billion in the year 2020, is projected to reach a revised size of US$6.7 Billion by 2027, growing at a CAGR of 5.3% over the analysis period 2020-2027.\n<\/p>\n

\nLevodopa \/ Carbidopa, one of the segments analyzed in the report, is projected to record a 6.6% CAGR and reach US$2.4 Billion by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the Dopamine Receptor Agonists segment is readjusted to a revised 4.7% CAGR for the next 7-year period.\n<\/p>\n

\nThe U.S. Market is Estimated at $1.3 Billion, While China is Forecast to Grow at 8.3% CAGR<\/strong>\n<\/p>\n

\nThe Parkinson’s Disease Treatment market in the U.S. is estimated at US$1.3 Billion in the year 2020. China, the world’s second largest economy, is forecast to reach a projected market size of US$1.4 Billion by the year 2027 trailing a CAGR of 8.4% over the analysis period 2020 to 2027.\n<\/p>\n

\nAmong the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 2.8% and 4.8% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 3.3% CAGR. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$882.1 Million by the year 2027.\n<\/p>\n

\nMAO-Inhibitors Segment to Record 5.6% CAGR<\/strong>\n<\/p>\n

\nIn the global MAO-Inhibitors segment, USA, Canada, Japan, China and Europe will drive the 5.6% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$594.3 Million in the year 2020 will reach a projected size of US$841.6 Million by the close of the analysis period.\n<\/p>\n

\nChina will remain among the fastest growing in this cluster of regional markets. Latin America will expand at a 6.8% CAGR through the analysis period.\n<\/p>\n

\nWhat’s New for 2022?<\/strong>\n<\/p>\n